FDA WARNING_LETTER - Midlab Incorporated - August 05, 2022

FDA WARNING_LETTER for Midlab Incorporated on August 05, 2022. Product: Drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA WARNING_LETTER for Midlab Incorporated on August 05, 2022. Product: Drugs. Access full analysis and detailed observations.

Violation Codes

21 CFR 211.100(a)

21 U.S.C. 331(d)

FD&C Act 301(d)

21 U.S.C. 321(p)

21 U.S.C. 355h

FD&C Act 501(a)(2)(B)

FD&C Act 321(g)(1)(C)

21 U.S.C. 331(a)

21.U.S.C. 355(a)

FD&C Act 321(g)(1)(B)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Midlab Incorporated

Inspection Date

August 5, 2022

Product Type

Drugs

Office

Division of Pharmaceutical Quality Operations II

People

ID: 692d5adb-89fe-47ab-b117-9203e518ebdc

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox